Cytokinetics Inc (CYTK)

NASDAQ
28.89
+0.78(+2.77%)
  • Volume:
    410,612
  • Bid/Ask:
    28.89/28.95
  • Day's Range:
    27.95 - 29.04

CYTK Overview

Prev. Close
28.11
Day's Range
27.95-29.04
Revenue
58.55M
Open
28.12
52 wk Range
14.71-31.41
EPS
-2.07
Volume
410,612
Market Cap
2.39B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,801,823
P/E Ratio
-
Beta
1.39
1-Year Change
16.64%
Shares Outstanding
83,063,040
Next Earnings Date
Aug 05, 2021
What is your sentiment on Cytokinetics Inc?
or
Vote to see community's results!

Cytokinetics Inc News

Cytokinetics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Cytokinetics Inc Company Profile

Cytokinetics Inc Company Profile

Employees
184

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Read More
  • Life Clips, Inc has skyrocketed roughly 3061% over the last two days after it announced a pivot into blockchain.
    0
    • 10 dollar jump today now $29.35 from $20.
      0
      • Yeah I saw it
        0
      • Life Clips, Inc has skyrocketed roughly 3061% over the last two days after it announced a pivot into blockchain.
        0
    • 20 soon.
      0
      • Is it worth continuing with this stock?
        0
        • Soon it will be reaching 3 months moving average $20+
          0
          • Different than other biopharma companies, they have a large portfolio. Bad news for short, an opportunity for long.
            0
            • I think there will be a bounce in the next days but do you think it's gonna go down more?
              0
          • sure if they can make some positive progress in their trials moving forward
            0
            • sure if they can make some positive progress in their trials moving forward
              0
              • Will this pop back up?
                0
                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.